Creo Medical Group (LON:CREO) Releases Earnings Results

Creo Medical Group (LON:CREO) posted its earnings results on Wednesday. The company reported GBX (2) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Creo Medical Group had a negative return on equity of 38.29% and a negative net margin of 268.57%.

Creo Medical Group Stock Down 1.4%

Shares of LON CREO traded down GBX 0.13 on Friday, hitting GBX 9.67. The company had a trading volume of 2,207,440 shares, compared to its average volume of 794,158. The company has a quick ratio of 2.19, a current ratio of 2.79 and a debt-to-equity ratio of 8.09. Creo Medical Group has a 12-month low of GBX 9.50 and a 12-month high of GBX 18.50. The firm has a market capitalization of £46.96 million, a P/E ratio of 9.67 and a beta of 1.56. The business has a 50 day moving average of GBX 12.54 and a two-hundred day moving average of GBX 12.80.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group reaffirmed a “house stock” rating and set a GBX 40 price target on shares of Creo Medical Group in a research report on Thursday, July 23rd.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.